Innovation has been a hallmark of biotechnology for decades and, despite some of the hardest sledding in many years, 2024 could be a bounce-back year for biotech stocks . The sector has suffered in this cycle. Investors have “rewarded” tech stocks and large-cap stocks for innovation, ignoring mid- and small-cap biotech stocks.
Somehow, investors forgot about just how favorable the backdrop is for biotech, especially if AI is as big of a game changer as promised. Why Biotech Stocks Have Been Stagnant..
. And Why That Could Change What caused many of these stocks to go nowhere for the last several years and miss out on the “bull market?” Maybe we can blame it on government interference in fixing prices of drugs, or more scrutiny of acquisitions. Maybe it was driven by concerns around impending drug-patent losses.
Ultimately, it doesn’t matter. Biotech stocks have undeniable long-term tailwinds. The reason the biotech sector is worth considering in 2024 is because of how fast technology is developing when it comes to medical drugs.
Pharmaceutical innovation has increased both territorially and production wise. There are some wild developments taking place that put ChatGPT to shame in my view. For example, innovations such as 3D bioprinting, which is synthesizing human organs and developing drugs from a patients’ own cells, will treat previously untreatable conditions and transform outcomes for patients.
How can investors not be losing their minds over that type of adv.
